26 results on '"Brucker, Sara Y."'
Search Results
2. Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations
- Author
-
Armbruster, Hannes, Schotte, Tilman, Götting, Isabell, Overkamp, Mathis, Granai, Massimo, Volmer, Lea Louise, Bahlinger, Veronika, Matovina, Sabine, Koch, André, Dannehl, Dominik, Engler, Tobias, Hartkopf, Andreas D., Brucker, Sara Y., Bonzheim, Irina, Fend, Falko, Staebler, Annette, and Montes-Mojarro, Ivonne
- Published
- 2024
- Full Text
- View/download PDF
3. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective
- Author
-
Krug, David, Banys-Paluchowski, Maggie, Brucker, Sara Y., Denkert, Carsten, Ditsch, Nina, Fasching, Peter A., Haidinger, Renate, Harbeck, Nadia, Heil, Jörg, Huober, Jens, Jackisch, Christian, Janni, Wolfgang, Kolberg, Hans-Christian, Loibl, Sibylle, Lüftner, Diana, van Mackelenbergh, Marion, Radosa, Julia C., Reimer, Toralf, Welslau, Manfred, Würstlein, Rachel, Untch, Michael, and Budach, Wilfried
- Published
- 2024
- Full Text
- View/download PDF
4. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
- Author
-
Fasching, Peter A., Hack, Carolin C., Nabieva, Naiba, Maass, Nicolai, Aktas, Bahriye, Kümmel, Sherko, Thomssen, Christoph, Wolf, Christopher, Kolberg, Hans-Christian, Brucker, Cosima, Janni, Wolfgang, Dall, Peter, Schneeweiss, Andreas, Marme, Frederik, Sütterlin, Marc W., Ruebner, Matthias, Theuser, Anna-Katharin, Kellner, Sara, Hofmann, Nadine M., Böhm, Sybille, Almstedt, Katrin, Lück, Hans-Joachim, Schmatloch, Sabine, Kalder, Matthias, Uleer, Christoph, Jurhasz-Böss, Ingolf, Hanf, Volker, Jackisch, Christian, Müller, Volkmar, Rack, Brigitte, Belleville, Erik, Wallwiener, Diethelm, Rody, Achim, Rauh, Claudia, Bayer, Christian M., Uhrig, Sabrina, Goossens, Chloë, Huebner, Hanna, Brucker, Sara Y., Hein, Alexander, Fehm, Tanja N., and Häberle, Lothar
- Published
- 2024
- Full Text
- View/download PDF
5. Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
- Author
-
Hein, Alexander, primary, Fasching, Peter A., primary, Hack, Carolin C., additional, Maass, Nicolai, additional, Aktas, Bahriye, additional, Kümmel, Sherko, additional, Thomssen, Christoph, additional, Wolf, Christopher, additional, Kolberg, Hans-Christian, additional, Brucker, Cosima, additional, Janni, Wolfgang, additional, Dall, Peter, additional, Schneeweiss, Andreas, additional, Marme, Frederik, additional, Ruebner, Matthias, additional, Theuser, Anna-Katharin, additional, Hofmann, Nadine M., additional, Böhm, Sybille, additional, Almstedt, Katrin, additional, Kellner, Sara, additional, Nabieva, Naiba, additional, Gass, Paul, additional, Sütterlin, Marc W., additional, Lück, Hans-Joachim, additional, Schmatloch, Sabine, additional, Kalder, Matthias, additional, Uleer, Christoph, additional, Juhasz-Böss, Ingolf, additional, Hanf, Volker, additional, Jackisch, Christian, additional, Müller, Volkmar, additional, Rack, Brigitte, additional, Belleville, Erik, additional, Wallwiener, Diethelm, additional, Rody, Achim, additional, Rauh, Claudia, additional, Bayer, Christian M., additional, Uhrig, Sabrina, additional, Goossens, Chloë, additional, Huebner, Hanna, additional, Brucker, Sara Y., additional, Häberle, Lothar, additional, and Fehm, Tanja N., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Zusammen sind wir Senologie!
- Author
-
Brucker, Sara Y., additional and Daigeler, Adrien, additional
- Published
- 2024
- Full Text
- View/download PDF
7. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs
- Author
-
Schneeweiss, Andreas, additional, Brucker, Sara Y., additional, Huebner, Hanna, additional, Volmer, Lea L., additional, Hack, Carolin C., additional, Seitz, Katharina, additional, Ruebner, Matthias, additional, Heublein, Sabine, additional, Thewes, Verena, additional, Lüftner, Diana, additional, Lux, Michael P., additional, Jurhasz-Böss, Ingolf, additional, Taran, Florin-Andrei, additional, Wimberger, Pauline, additional, Anetsberger, Daniel, additional, Beierlein, Milena, additional, Schmidt, Marcus, additional, Radosa, Julia, additional, Müller, Volkmar, additional, Janni, Wolfgang, additional, Rack, Brigitte, additional, Belleville, Erik, additional, Untch, Michael, additional, Thill, Marc, additional, Ditsch, Nina, additional, Aktas, Bahriye, additional, Nel, Ivonne, additional, Kolberg, Hans-Christian, additional, Engerle, Tobias, additional, Tesch, Hans, additional, Roos, Christian, additional, Budden, Christina, additional, Neubauer, Hans, additional, Hartkopf, Andreas D., additional, Fehm, Tanja N., additional, and Fasching, Peter A., additional
- Published
- 2024
- Full Text
- View/download PDF
8. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry
- Author
-
Hartkopf, Andreas D., primary, Walter, Christina B., primary, Kolberg, Hans-Christian, additional, Hadji, Peyman, additional, Tesch, Hans, additional, Fasching, Peter A., additional, Ettl, Johannes, additional, Lüftner, Diana, additional, Wallwiener, Markus, additional, Müller, Volkmar, additional, Beckmann, Matthias W., additional, Belleville, Erik, additional, Huebner, Hanna, additional, Uhrig, Sabrina, additional, Goossens, Chloë, additional, Link, Theresa, additional, Hielscher, Carsten, additional, Mundhenke, Christoph, additional, Kurbacher, Christian, additional, Wuerstlein, Rachel, additional, Untch, Michael, additional, Janni, Wolfgang, additional, Taran, Florin-Andrei, additional, Michel, Laura L., additional, Lux, Michael P., additional, Wallwiener, Diethelm, additional, Brucker, Sara Y., additional, Fehm, Tanja N., additional, Häberle, Lothar, additional, and Schneeweiss, Andreas, additional
- Published
- 2024
- Full Text
- View/download PDF
9. Long-Term Follow-Up Regarding Pain Relief, Fertility, and Re-Operation after Surgery for Deep Endometriosis.
- Author
-
Drechsel-Grau, Alexander, Grube, Marcel, Neis, Felix, Schoenfisch, Birgitt, Kommoss, Stefan, Rall, Katharina, Brucker, Sara Y., Kraemer, Bernhard, and Andress, Juergen
- Subjects
REOPERATION ,CHILDBIRTH ,FERTILITY ,INFERTILITY ,ENDOMETRIOSIS ,ANALGESIA - Abstract
Background: Endometriosis is known to be a common chronic disease that often affects the quality of life of patients. Especially for deep endometriosis (DE), the most challenging form of the disease, surgery remains an important component of treatment. However, long-term outcomes after surgery are poorly studied. Therefore, we aimed to evaluate the postoperative clinical course of women with DE who underwent surgery, particularly with regard to pain relief, fertility, and re-operations. Methods: Thus, women who underwent surgical treatment for DE between 2005 and 2015 were included in this retrospective questionnaire-based analysis. Results: A total of 87.0% of the patients who underwent surgery for pain reported a postoperative relief of their complaints. Moreover, 44.6% even stated that they were free of pain at the time of the questionnaire. Patients who underwent surgery for infertility and tried to become pregnant postoperatively gave birth to a child in 45.9% of cases. Approximately one-third of the patients had to undergo another surgery because of endometriosis-related symptoms. The main reasons for re-operation were pain and infertility. The median time to re-operation was 2.1 years. Conclusions: In this extraordinarily long follow-up with a remarkable response rate, we show that surgical treatment of DE leads to pain relief and improved fertility in most cases. However, the risk of recurrence and the need for re-operation remains remarkable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Placental growth factor mediates pathological uterine angiogenesis by activating the NFAT5-SGK1 signaling axis in the endometrium: implications for preeclampsia development.
- Author
-
Raja Xavier, Janet P., Okumura, Toshiyuki, Apweiler, Melina, Chacko, Nirzari A., Singh, Yogesh, Brucker, Sara Y, Takeda, Satoru, Lang, Florian, and Salker, Madhuri S
- Subjects
PLACENTAL growth factor ,PREGNANCY complications ,UTERINE artery ,ENDOTHELIAL cells ,EXTRACELLULAR matrix ,NEOVASCULARIZATION - Abstract
After menstruation the uterine spiral arteries are repaired through angiogenesis. This process is tightly regulated by the paracrine communication between endometrial stromal cells (EnSCs) and endothelial cells. Any molecular aberration in these processes can lead to complications in pregnancy including miscarriage or preeclampsia (PE). Placental growth factor (PlGF) is a known contributing factor for pathological angiogenesis but the mechanisms remain poorly understood. In this study, we investigated whether PlGF contributes to pathological uterine angiogenesis by disrupting EnSCs and endothelial paracrine communication. We observed that PlGF mediates a tonicity-independent activation of nuclear factor of activated T cells 5 (NFAT5) in EnSCs. NFAT5 activated downstream targets including SGK1, HIF-1α and VEGF-A. In depth characterization of PlGF - conditioned medium (CM) from EnSCs using mass spectrometry and ELISA methods revealed low VEGF-A and an abundance of extracellular matrix organization associated proteins. Secreted factors in PlGF-CM impeded normal angiogenic cues in endothelial cells (HUVECs) by downregulating Notch-VEGF signaling. Interestingly, PlGF-CM failed to support human placental (BeWo) cell invasion through HUVEC monolayer. Inhibition of SGK1 in EnSCs improved angiogenic effects in HUVECs and promoted BeWo invasion, revealing SGK1 as a key intermediate player modulating PlGF mediated anti-angiogenic signaling. Taken together, perturbed PlGF-NFAT5-SGK1 signaling in the endometrium can contribute to pathological uterine angiogenesis by negatively regulating EnSCs-endothelial crosstalk resulting in poor quality vessels in the uterine microenvironment. Taken together the signaling may impact on normal trophoblast invasion and thus placentation and, may be associated with an increased risk of complications such as PE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Rel Family Transcription Factor NFAT5 Upregulates COX2 via HIF-1α Activity in Ishikawa and HEC1a Cells
- Author
-
Okumura, Toshiyuki, primary, Raja Xavier, Janet P., additional, Pasternak, Jana, additional, Yang, Zhiqi, additional, Hang, Cao, additional, Nosirov, Bakhtiyor, additional, Singh, Yogesh, additional, Admard, Jakob, additional, Brucker, Sara Y., additional, Kommoss, Stefan, additional, Takeda, Satoru, additional, Staebler, Annette, additional, Lang, Florian, additional, and Salker, Madhuri S., additional
- Published
- 2024
- Full Text
- View/download PDF
12. Human tissue-resident peritoneal macrophages reveal resistance towards oxidative cell stress induced by non-invasive physical plasma
- Author
-
Schultze-Rhonhof, Laura, primary, Marzi, Julia, additional, Carvajal Berrio, Daniel Alejandro, additional, Holl, Myriam, additional, Braun, Theresa, additional, Schäfer-Ruoff, Felix, additional, Andress, Jürgen, additional, Bachmann, Cornelia, additional, Templin, Markus, additional, Brucker, Sara Y., additional, Schenke-Layland, Katja, additional, and Weiss, Martin, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Optical Emission Spectroscopy for the Real-Time Identification of Malignant Breast Tissue
- Author
-
Guergan, Selin, primary, Boeer, Bettina, additional, Fugunt, Regina, additional, Helms, Gisela, additional, Roehm, Carmen, additional, Solomianik, Anna, additional, Neugebauer, Alexander, additional, Nuessle, Daniela, additional, Schuermann, Mirjam, additional, Brunecker, Kristin, additional, Jurjut, Ovidiu, additional, Boehme, Karen A., additional, Dammeier, Sascha, additional, Enderle, Markus D., additional, Bettio, Sabrina, additional, Gonzalez-Menendez, Irene, additional, Staebler, Annette, additional, Brucker, Sara Y., additional, Kraemer, Bernhard, additional, Wallwiener, Diethelm, additional, Fend, Falko, additional, and Hahn, Markus, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
- Author
-
Hein, Alexander, primary, Fasching, Peter A., primary, Hack, Carolin C., additional, Maass, Nicolai, additional, Aktas, Bahriye, additional, Kümmel, Sherko, additional, Thomssen, Christoph, additional, Wolf, Christopher, additional, Kolberg, Hans-Christian, additional, Brucker, Cosima, additional, Janni, Wolfgang, additional, Dall, Peter, additional, Schneeweiss, Andreas, additional, Marme, Frederik, additional, Ruebner, Matthias, additional, Theuser, Anna-Katharin, additional, Hofmann, Nadine M., additional, Böhm, Sybille, additional, Almstedt, Katrin, additional, Kellner, Sara, additional, Nabieva, Naiba, additional, Gass, Paul, additional, Sütterlin, Marc W., additional, Lück, Hans-Joachim, additional, Schmatloch, Sabine, additional, Kalder, Matthias, additional, Uleer, Christoph, additional, Juhasz-Böss, Ingolf, additional, Hanf, Volker, additional, Jackisch, Christian, additional, Müller, Volkmar, additional, Rack, Brigitte, additional, Belleville, Erik, additional, Wallwiener, Diethelm, additional, Rody, Achim, additional, Rauh, Claudia, additional, Bayer, Christian M., additional, Uhrig, Sabrina, additional, Goossens, Chloë, additional, Huebner, Hanna, additional, Brucker, Sara Y., additional, Häberle, Lothar, additional, and Fehm, Tanja N., additional
- Published
- 2024
- Full Text
- View/download PDF
15. Excessive endometrial PlGF- Rac1 signalling underlies endometrial cell stiffness linked to pre-eclampsia.
- Author
-
Raja Xavier, Janet P., Rianna, Carmela, Hellwich, Emily, Nikolou, Iliana, Lankapalli, Aditya Kumar, Brucker, Sara Y., Singh, Yogesh, Lang, Florian, Schäffer, Tilman E., and Salker, Madhuri S.
- Subjects
TROPHOBLAST ,EXTRACELLULAR matrix proteins ,CYTOSKELETON ,PLACENTAL growth factor ,PREECLAMPSIA ,PATHOLOGICAL physiology ,ATOMIC force microscopy - Abstract
Cell stiffness is regulated by dynamic interaction between ras-related C3 botulinum toxin substrate 1 (Rac1) and p21 protein-activated kinase 1 (PAK1) proteins, besides other biochemical and molecular regulators. In this study, we investigated how the Placental Growth Factor (PlGF) changes endometrial mechanics by modifying the actin cytoskeleton at the maternal interface. We explored the global effects of PlGF in endometrial stromal cells (EnSCs) using the concerted approach of proteomics, atomic force microscopy (AFM), and electrical impedance spectroscopy (EIS). Proteomic analysis shows PlGF upregulated RhoGTPases activating proteins and extracellular matrix organization-associated proteins in EnSCs. Rac1 and PAK1 transcript levels, activity, and actin polymerization were significantly increased with PlGF treatment. AFM further revealed an increase in cell stiffness with PlGF treatment. The additive effect of PlGF on actin polymerization was suppressed with siRNA-mediated inhibition of Rac1, PAK1, and WAVE2. Interestingly, the increase in cell stiffness by PlGF treatment was pharmacologically reversed with pravastatin, resulting in improved trophoblast cell invasion. Taken together, aberrant PlGF levels in the endometrium can contribute to an altered pre-pregnancy maternal microenvironment and offer a unifying explanation for the pathological changes observed in conditions such as pre-eclampsia (PE). High levels of placental growth factor can result in a stiffer microenvironment milieu impeding trophoblast invasion of endometrial cells prior to pregnancy, providing insight into the pathogenesis of pre-eclampsia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. ENABLE: App-based digital capture and intervention of patientreported quality of life, adverse events, and treatment satisfaction in breast cancer - study protocol for a randomized controlled trial
- Author
-
Deutsch, Thomas M, primary, Volmer, Léa L., additional, Feisst, Manuel, additional, Bodenbeck, Laura, additional, Hassdenteufel, Kathrin, additional, Le, Thao Vy, additional, Breit, Christiane, additional, Stefanovic, Stefan, additional, Bauer, Armin, additional, Anders, Carolin, additional, Weinert, Lina, additional, Engler, Tobias, additional, Hartkopf, Andreas D., additional, Pfeifer, Nico, additional, Escher, Pascal, additional, Mausch, Marc, additional, Heinze, Oliver, additional, Suetterlin, Marc, additional, Brucker, Sara Y., additional, Schneeweiss, Andreas, additional, and Wallwiener, Markus, additional
- Published
- 2024
- Full Text
- View/download PDF
17. Die CAPTOR-BC-Studie.
- Author
-
Fasching, Peter A., Brucker, Sara Y., Huebner, Hanna, Thewes, Verena, Volmer, Lea L., Hartkopf, Andreas, Engler, Tobias, Hack, Carolin C, Juhasz-Böss, Ingolf, Kolberg, Hans-Christian, Lüftner, Diana, Lux, Michael P., Schmidt, Marcus, Tesch, Hans, Thill, Marc, Untch, Michael, Link, Theresa, Nel, Ivonne, Neubauer, Hans, and Rack, Brigitte
- Published
- 2024
- Full Text
- View/download PDF
18. Die BETTER-CARE-Studie: Bedarfsadaptierte und individualisierte Versorgung von Patient*innen nach der Therapie von primärem Brustkrebs.
- Author
-
Horn, Anna, Bauer, Armin, Baumeister, Harald, Brucker, Sara Y., Deutsch, Thomas M., Heuschmann, Peter U., Hügen, Klemens, Pryss, Rüdiger, Szczesny, Andrea, and Wöckel, Achim
- Published
- 2024
- Full Text
- View/download PDF
19. Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome.
- Author
-
Seller, Anna, Tegeler, Christian M., Mauermann, Jonas, Schreiber, Tatjana, Hagelstein, Ilona, Liebel, Kai, Koch, André, Heitmann, Jonas S., Greiner, Sarah M., Hayn, Clara, Dannehl, Dominik, Engler, Tobias, Hartkopf, Andreas D., Hahn, Markus, Brucker, Sara Y., Salih, Helmut R., and Märklin, Melanie
- Subjects
CANCER patients ,KILLER cells ,CYTOTOXIC T cells ,BREAST cancer ,BREAST ,CARCINOMA in situ ,DUCTAL carcinoma - Abstract
Ligands of the natural killer group 2D (NKG2DL) family are expressed on malignant cells and are usually absent from healthy tissues. Recognition of NKG2DLs such as MICA/B and ULBP1-3 by the activating immunoreceptor NKG2D, expressed by NK and cytotoxic T cells, stimulates anti-tumor immunity in breast cancer. Upregulation of membrane-bound NKG2DLs in breast cancer has been demonstrated by immunohistochemistry. Tumor cells release NKG2DLs via proteolytic cleavage as soluble (s)NKG2DLs, which allows for effective immune escape and is associated with poor prognosis. In this study, we collected serum from 140 breast cancer (BC) and 20 ductal carcinoma in situ (DCIS) patients at the time of initial diagnosis and 20 healthy volunteers (HVs). Serum levels of sNKG2DLs were quantified through the use of ELISA and correlated with clinical data. The analyzed sNKG2DLs were low to absent in HVs and significantly higher in BC patients. For some of the ligands analyzed, higher sNKG2DLs serum levels were associated with the classification of malignant tumor (TNM) stage and grading. Low sMICA serum levels were associated with significantly longer progression-free (PFS) and overall survival (OS). In conclusion, we provide the first insights into sNKG2DLs in BC patients and suggest their potential role in tumor immune escape in breast cancer. Furthermore, our observations suggest that serum sMICA levels may serve as a prognostic parameter in the patients analyzed in this study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Contributors to Volume 2
- Author
-
Abouljoud, Marwan, Abu-Gazala, Samir, Akbulut, Sami, Al Harakeh, Hasan, Aleassa, Essa M., Alqahtani, Saleh A., Ascher, Nancy L., Asolati, Massimo, Aucejo, Federico, Bababekov, Yanik J., Baker, Talia, Barth, Rolf N., Bayer, Johanna, Benedetti, Enrico, Benedetti, Claudia, Bhati, Chandra S., Bizzaro, Deborah, Bond, Geoffrey J., Braun, Hillary J., Broelsch, Christopher E., Broering, Dieter C., Bromberg, Jonathan S., Brown, Robert S., Jr., Brucker, Sara Y., Bui, James T., Burra, Patrizia, Cagliani, Joaquin, Carr-Boyd, Peter D., Cascalho, Marilia, Cattral, Mark S., Chan, See Ching, Chen, Chao-long, Cherqui, Daniel, Ciria, Ruben, Crane, Alice, Cravedi, Paolo, David Kwon, Choon Hyuck, de Magnee, Catherine, Delmonico, Francis L., De Prisco, Gregory, Di Bella, Caterina, Di Cocco, Pierpaolo, di Sabato, Diego, Diaz, Geraldine, Dudkowski, Morgan, Eagle, Elizabeth, Eisenson, Daniel, Emond, Jean C., Emre, Sukru, Ericzon, Bo-Göran, Florman, Sander S., Freise, Chris E., Fronek, Jiri, Fung, John J., Furian, Lucrezia, Ganoza, Armando, Genedy, L., Giacomo, Germani, Giglio, Mariano Cesare, Gorrell, David, Gruessner, Rainer W.G., Gruessner, Angelika C., Hashimoto, Koji, Heffron, Natalie, Heffron, Thomas G., Heimbach, Julie, Hester, Joanna, Hibi, Taizo, Hirao, Hirofumi, Humar, Abhinav, Hwang, Shin, Iesari, Samuele, Ince, Volkan, Isik, Burak, Issa, Fadi, Jacobs, Cheryl, Järvholm, Stina, Jeon, Hoonbae, Johannesson, Liza, Kalis, Ann, Kaplan, Alyson, Khan, Khalid, Khanna, Ajai, Kim, Ki H., Kim, Wan-Joon, Kittle, Haley, Knechtle, Stuart, Koppe, Sean, Kord, Ali, Kristek, Jakub, Kumar, Shiva, Kupiec-Weglinski, Jerzy W., Lake, John, LaMattina, John C., Lee, Sung-Gyu, Lerut, Jan, Lin, Tsan-Shiun, Lo Bianco, Emanuela, Lo, Chung Mau, Malago, Massimo, Malik, Saad, Maluf, Daniel G., Marique, Lancelot, Martin, Dominique E., Mazariegos, George V., Mazariegos, George, McCallion, Oliver, McGraw, Lisa A., Meier, Raphael P.H., Merola, Jonathan, Miller, Charles, Moon, Deok-Bog, Moore, Hunter B., Muller, Yannick D., Nadalin, Silvio, Nada, Ahmed A., Nakamura, Kojiro, Ogle, Brenda M., Ogura, Yasuhiro, Olausson, Michael, Olthoff, Kim M., Ong, Aldwin, Paci, Philippe, Piedrahita, Jorge A., Pinna, Antonio, Pirotte, Thierry, Pita, Alejandro, Platt, Jeffrey L., Pomfret, Elizabeth Anne, Pomposelli, James J., Quintini, Cristiano, Reding, Raymond, Renz, John F., Rizzari, Michael D., Roberts, John P., Roggen, Francine, Roll, Garrett R., Sachs, David, Salerno, David M., Samstein, Benjamin, Schmitz, Robin, Selzner, Nazia, Senzolo, Marco, Sonmez, Tayfun, Stock, Peter G., Tabrizian, Parissa, Tambucci, Roberto, Tanaka, Koichi, Testa, Giuliano, Thaker, Sarang, Thomson, Mary, Tranäng, Marie, Troisi, Roberto I., Tulla, Kiara A., Tully, Madeline, Tumeh, John, Tzvetanov, Ivo, Umman, Veysel, Unver, Utku, Vallabhajosyula, Prashanth, Wahid, Nabeel, Wilczek, Henryk E., Williams, Nicola, Xie, Julia, Yamada, Kazuhiko, Yilmaz, Sezai, Zanetto, Alberto, Zaza, Gianluigi, and Zeytunlu, Murat
- Published
- 2024
- Full Text
- View/download PDF
21. Happy Birthday, Senologie!
- Author
-
Brucker, Sara Y., Schneeweiss, Andreas, Schulz-Wendtland, Rüdiger, and Wallwiener, Diethelm
- Published
- 2024
- Full Text
- View/download PDF
22. The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.
- Author
-
Ziegler P, Hartkopf AD, Wallwiener M, Häberle L, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Michel LL, Belleville E, Wimberger P, Hielscher C, Huebner H, Uhrig S, Wurmthaler LA, Hack CC, Mundhenke C, Kurbacher C, Fasching PA, Wuerstlein R, Untch M, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, and Goossens C
- Subjects
- Humans, Female, Middle Aged, Aged, Prospective Studies, Surveys and Questionnaires, Adult, Prognosis, Progression-Free Survival, Neoplasm Metastasis, Receptor, ErbB-2 metabolism, Registries, Exercise, Breast Neoplasms pathology, Breast Neoplasms mortality
- Abstract
Background: Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the different molecular cancer subtypes. Therefore, we here evaluated the effect of physical activity on progression-free and overall survival (PFS, OS) in metastatic breast cancer, specifically looking at molecular subtypes., Methods: International Physical Activity Questionnaire (IPAQ) questionnaires, filled out by patients enrolled in the prospective PRAEGNANT registry (NCT02338167; n = 1,270) were used to calculate metabolic equivalent task (MET) minutes, which were subsequently categorized into low (n = 138), moderate (n = 995) or high IPAQ categories (n = 137). Cox regression analyses were used to evaluate the impact of IPAQ categories and its interaction with molecular subtypes on PFS and OS., Results: Patient and tumor characteristics were equally distributed across IPAQ categories. HER2pos, HRpos and TNBC were present in 23.1%, 65.7% and 11.2% of patients, respectively. IPAQ scores did not have an impact on PFS and OS in addition to established prognostic factors, either overall or in particular molecular subtypes (PFS: p = 0.33 and OS: p = 0.08, likelihood ratio test). Exploratory analyses showed higher overall survival rates for high IPAQ categories compared to low/moderate IPAQ categories in luminal B-like breast cancer., Conclusions: Self-reported physical activity using the IPAQ questionnaire did not significantly affect PFS or OS in patients suffering from metastatic breast cancer. Nevertheless, some hypothesis-generating differences between molecular subtypes could be observed, which may be interesting to evaluate further., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.
- Author
-
Fasching PA, Hu C, Hart SN, Ruebner M, Polley EC, Gnanaolivu RD, Hartkopf AD, Huebner H, Janni W, Hadji P, Tesch H, Uhrig S, Ettl J, Lux MP, Lüftner D, Wallwiener M, Wurmthaler LA, Goossens C, Müller V, Beckmann MW, Hein A, Anetsberger D, Belleville E, Wimberger P, Untch M, Ekici AB, Kolberg HC, Hartmann A, Taran FA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Häberle L, and Couch FJ
- Abstract
Germline mutations in BRCA1 and BRCA2 (gBRCA1/2) are required for a PARP inhibitor therapy in patients with HER2-negative (HER2-) advanced breast cancer (aBC). However, little is known about the prognostic impact of gBRCA1/2 mutations in aBC patients treated with chemotherapy. This study aimed to investigate the frequencies and prognosis of germline and somatic BRCA1/2 mutations in HER2- aBC patients receiving the first chemotherapy in the advanced setting. Patients receiving their first chemotherapy for HER2- aBC were retrospectively selected from the prospective PRAEGNANT registry (NCT02338167). Genotyping of 26 cancer predisposition genes was performed with germline DNA of 471 patients and somatic tumor DNA of 94 patients. Mutation frequencies, progression-free and overall survival (PFS, OS) according to germline mutation status were assessed. gBRCA1/2 mutations were present in 23 patients (4.9%), and 33 patients (7.0%) had mutations in other cancer risk genes. Patients with a gBRCA1/2 mutation had a better OS compared to non-mutation carriers (HR: 0.38; 95%CI: 0.17-0.86). PFS comparison was not statistically significant. Mutations in other risk genes did not affect prognosis. Two somatic BRCA2 mutations were found in 94 patients without gBRCA1/2 mutations. Most frequently somatic mutated genes were TP53 (44.7%), CDH1 (10.6%) and PTEN (6.4%). In conclusion, aBC patients with gBRCA1/2 mutations had a more favorable prognosis under chemotherapy compared to non-mutation carriers. The mutation frequency of ~5% with gBRCA1/2 mutations together with improved outcome indicates that germline genotyping of all metastatic patients for whom a PARP inhibitor therapy is indicated should be considered., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
24. Ultrasound-guided breast-conserving surgery compared to conventional breast-conserving surgery.
- Author
-
Boeer B, Obermoser J, Marx M, Schönfisch B, Grube M, Röhm C, Helms G, Fugunt R, Hartkopf AD, Brucker SY, and Hahn M
- Abstract
Purpose: The goal of breast-conserving surgery is to achieve negative tumor margins, since insufficient marginal distance is associated with more local and distant recurrences. This study investigates whether IOUS (intraoperative ultrasound) can reduce the re-resection rate compared to standard breast surgery, regardless of tumor biology and focality., Materials and Methods: The present study is a monocentric, prospective, randomized, and non-blinded parallel group study conducted between 7/2015 and 2/2018. Patients with sonographically visible breast cancer were randomized into two study arms: 1) breast-conserving surgery with IOUS; 2) conventional arm., Results: 364 patients were included in the study and underwent surgery. Tumor biology, size, and focality were equally distributed in both groups (p = 0.497). The study arms did not differ significantly in the proportion of preoperative wire markings (p= 0.084), specimen weight (p = 0.225), surgery duration (p = 0.849), and the proportion of shavings taken intraoperatively (p = 0.903). Positive margins were present in 16.6% of the cases in the IOUS arm and in 20.8% in the conventional arm (p = 0.347). Re-operation was necessary after intraoperative shavings in 14.4% of cases in the US arm and in 21.3% in the conventional arm (p = 0.100)., Conclusion: Although the present study showed a clear difference in the rate of positive tumor margins with IOUS compared to conventional breast surgery without IOUS, this was not statistically significant in contrast to the current literature. This could be due to the high expertise of the breast surgeons, the precise wire marking, or the fact that the IOUS technique was not standardized., Competing Interests: The authors declare that they have no conflict of interest., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
- Author
-
Hack CC, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Nabieva N, Gass P, Sütterlin MW, Lück HJ, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Goossens C, Huebner H, Brucker SY, Häberle L, Fehm TN, Hein A, and Fasching PA
- Abstract
[This corrects the article DOI: 10.1055/a-2238-3153.]., Competing Interests: Conflict of Interest P. G. received honoraria from Novartis, MSD, and AstraZeneca. K. A. received speaker honoraria from Roche Pharma AG, Pfizer Pharma GmbH and AstraZeneca. C. C. H. received honoraria from Roche, Pfizer, Novartis, AstraZeneca, Gilead, Daiichi Sankyo, Eisai, Gilead and MSD, and received travel grants from Daiichi Sankyo. B. A. received honoraria from AstraZeneca, Gilead, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Stemline, Teva, Tesaro, Daiichi Sankyo and Pfizer. Received travel grants from AstraZeneca, Roche, Novartis, Celgene, Lilly, Eisai, Stemline, Daiichi Sankyo and Pfizer. Participated in the data safety monitoring board or advisory boards for AstraZeneca, Gilead, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Tesaro, Daiichi Sankyo and Pfizer. S. K. received honoraria from Amgen, Celgene, Daiichi Sankyo, Novartis and Roche. C. T. received honoraria for advisory boards and lectures from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Mylan, Nanostring, Novartis, Pfizer, Pierre Fabre, Puma, Roche, Seagen, Vifor. H.-C. K. has received honoraria from Pfizer, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, Daiichi Sankyo, Gilead, Zuellig, travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro, Gilead, AstraZeneca, Zuellig, Stemline, participated in data safety monitoring board or advisory boards for Pfizer, Novartis, SurgVision, Carl Zeiss Meditec, Amgen, Onkowissen, MSD, Gilead, Daiichi Sankyo, Seagen, Genomic Health/Exact Sciences, Agendia, Lilly and owns stock of Theraclion SA. W. J. has received research grants and/or honoraria from Sanofi-Aventis, Daiichi Sankyo, Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, GSK, Eisai, Cellgene and Johnson & Johnson. A. S. reported grants from Celgene, Roche and AbbVie. Personal fees from Cellgene, Roche, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Bayer, Amgen, and Pierre Fabre, and travel grants from Celgene, Roche, Pfizer and AstraZeneca. F. M. received honoraria from Amgen, AstraZeneca, Celgene, Clovis Oncology, CureVac, Eisai, Genomic Health, GlaxoSmithKline, Immunomedics, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, PharmaMar, Roche, Seattle Genetics, Tesaro. M. W. S. received honoraria from AstraZeneca, Pfizer, Clovis, Mylan, Roche, Gedeon Richter, Carl Zeiss Meditec, travel support from Pfizer, Carl Zeiss Meditec. C. J. reports personal fees from AstraZeneca, Exact Sciences, Lilly, Novartis and Roche. V. M. received speaker honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GSK, Pfizer, MSD, Medac, Novartis, Roche, Teva, Seagen, Onkowissen, high5 Oncology, Medscape, Gilead. Consultancy honoraria from Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, Sanofi, Seagen, Gilead. Institutional research support from Novartis, Roche, Seagen, Genentech. Travel grants: Roche, Pfizer, Daiichi Sankyo. E. B. received honoraria from Novartis, Hexal, BMS, Lilly, Pfizer, Roche, MSD, Bayer, Ipsen, Bluebird, Braun and onkowissen.de for consulting, clinical research management or medical education activities. S. Y. B. has received honoraria from Roche Pharma, Novartis, Pfizer, MSD, Teva, AstraZeneca. T. N. F. has received honoraria from Novartis, Roche, Pfizer, Teva, Daiichi Sankyo, AstraZeneca and MSD. P. A. F. reports personal fees from Novartis, grants from Biontech, personal fees from Pfizer, personal fees from Daiichi Sankyo, personal fees from AstraZeneca, personal fees from Eisai, personal fees from MSD, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre, personal fees from SeaGen, personal fees from Roche, personal fees from Hexal, personal fees from Agendia, personal fees from Gilead. C.R. received honoraria from MSD and AstraZeneca, travel expenses from the Swiss Society of Senology and the Swiss Society of Gynecology. N.N. is currently an employee of Novartis and has received travel support from Novartis and TEVA in the past. All of the remaining authors declare that they do not have any conflicts of interest., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
- Published
- 2024
- Full Text
- View/download PDF
26. Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
- Author
-
Hack CC, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Sütterlin MW, Lück HJ, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Goossens C, Huebner H, Brucker SY, Häberle L, Fehm TN, Hein A, and Fasching PA
- Abstract
Introduction: Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Nevertheless, not much is known about the patient selection for this population in clinical practice. Therefore, this study analyzed the prognosis and patient characteristics of postmenopausal patients selected for a five-year upfront letrozole therapy., Patients and Methods: From 2009 to 2011, 3529 patients were enrolled into the adjuvant phase IV PreFace clinical trial (NCT01908556). Postmenopausal hormone receptor-positive BC patients, for whom an upfront five-year therapy with letrozole (2.5 mg/day) was indicated, were eligible. Disease-free survival (DFS), overall survival (OS) and safety in relation to patient and tumor characteristics were assessed., Results: 3297 patients started letrozole therapy. The majority of patients (n = 1639, 57%) completed the five-year treatment. 34.5% of patients continued with endocrine therapy after the mandated five-year endocrine treatment. Five-year DFS rates were 89% (95% CI: 88-90%) and five-year OS rates were 95% (95% CI: 94-96%). In subgroup analyses, DFS rates were 83%, 84% and 78% for patients with node-positive disease, G3 tumor grading, and pT3 tumors respectively. The main adverse events (any grade) were pain and hot flushes (66.8% and 18.3% of patients)., Conclusions: The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies., Competing Interests: Conflict of Interest P. G. received honoraria from Novartis, MSD, and AstraZeneca. K. A. received speaker honoraria from Roche Pharma AG, Pfizer Pharma GmbH and AstraZeneca. C. C. H. received honoraria from Roche, Pfizer, Novartis, AstraZeneca, Gilead, Daiichi Sankyo, Eisai, Gilead and MSD, and received travel grants from Daiichi Sankyo. B. A. received honoraria from AstraZeneca, Gilead, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Stemline, Teva, Tesaro, Daiichi Sankyo and Pfizer. Received travel grants from AstraZeneca, Roche, Novartis, Celgene, Lilly, Eisai, Stemline, Daiichi Sankyo and Pfizer. Participated in the data safety monitoring board or advisory boards for AstraZeneca, Gilead, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Tesaro, Daiichi Sankyo and Pfizer. S. K. received honoraria from Amgen, Celgene, Daiichi Sankyo, Novartis and Roche. C. T. received honoraria for advisory boards and lectures from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Mylan, Nanostring, Novartis, Pfizer, Pierre Fabre, Puma, Roche, Seagen, Vifor. H.-C. K. has received honoraria from Pfizer, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, Daiichi Sankyo, Gilead, Zuellig, travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro, Gilead, AstraZeneca, Zuellig, Stemline, participated in data safety monitoring board or advisory boards for Pfizer, Novartis, SurgVision, Carl Zeiss Meditec, Amgen, Onkowissen, MSD, Gilead, Daiichi Sankyo, Seagen, Genomic Health/Exact Sciences, Agendia, Lilly and owns stock of Theraclion SA. W. J. has received research grants and/or honoraria from Sanofi-Aventis, Daiichi Sankyo, Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, GSK, Eisai, Cellgene and Johnson & Johnson. A. S. reported grants from Celgene, Roche and AbbVie. Personal fees from Cellgene, Roche, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Bayer, Amgen, and Pierre Fabre, and travel grants from Celgene, Roche, Pfizer and AstraZeneca. F. M. received honoraria from Amgen, AstraZeneca, Celgene, Clovis Oncology, CureVac, Eisai, Genomic Health, GlaxoSmithKline, Immunomedics, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, PharmaMar, Roche, Seattle Genetics, Tesaro. M. W. S. received honoraria from AstraZeneca, Pfizer, Clovis, Mylan, Roche, Gedeon Richter, Carl Zeiss Meditec, travel support from Pfizer, Carl Zeiss Meditec. C. J. reports personal fees from AstraZeneca, Exact Sciences, Lilly, Novartis and Roche. V. M. received speaker honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GSK, Pfizer, MSD, Medac, Novartis, Roche, Teva, Seagen, Onkowissen, high5 Oncology, Medscape, Gilead. Consultancy honoraria from Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, Sanofi, Seagen, Gilead. Institutional research support from Novartis, Roche, Seagen, Genentech. Travel grants: Roche, Pfizer, Daiichi Sankyo. E. B. received honoraria from Novartis, Hexal, BMS, Lilly, Pfizer, Roche, MSD, Bayer, Ipsen, Bluebird, Braun and onkowissen.de for consulting, clinical research management or medical education activities. S. Y. B. has received honoraria from Roche Pharma, Novartis, Pfizer, MSD, Teva, AstraZeneca. T. N. F. has received honoraria from Novartis, Roche, Pfizer, Teva, Daiichi Sankyo, AstraZeneca and MSD. P. A. F. reports personal fees from Novartis, grants from Biontech, personal fees from Pfizer, personal fees from Daiichi Sankyo, personal fees from AstraZeneca, personal fees from Eisai, personal fees from MSD, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre, personal fees from SeaGen, personal fees from Roche, personal fees from Hexal, personal fees from Agendia, personal fees from Gilead. C.R. received honoraria from MSD and AstraZeneca, travel expenses from the Swiss Society of Senology and the Swiss Society of Gynecology. All of the remaining authors declare that they do not have any conflicts of interest., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.